GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: KRP-AM1977 | Lasvic®
lascufloxacin is an approved drug (Japan)
Compound class:
Synthetic organic
Comment: Lascufloxacin is a fluoroquinolone antibacterial that is effective against Gram-positive respiratory pathogenic bacteria and is highly distributed in the lung [1].
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| In September 2019, an oral formulation of lascufloxacin hydrochloride (Lasvic®) was granted approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of otorhinolaryngological and respiratory tract infections, including community-acquired pneumonia (CAP) [2]. |